Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

NCT01437267 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Typhoid Fever

Interventions

BIOLOGICAL: Vi-CRM197 vaccine
BIOLOGICAL: Pneumococcal conjugate vaccine
BIOLOGICAL: Vi Polysaccharide (PS) vaccine

Sponsor

Novartis